CRDF

Cardiff Oncology, Inc.

CRDF | $4.34 -0.69% -0.69% 610K

(0.0% 1d) (-11.9% 1m) (219.0% 1y) (0.0% 2d) (0.0% 3d) (-17.2% 7d) (-61.45% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 193,898,913
http://www.cardiffoncology.com
Sec Filling | Patents | 14 employees

(US) Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.

cancer treatment

add to watch list Paper trade email alert is off

Press-releases

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
Published: 2024-04-08 (Crawled : 20:00) - globenewswire.com
CRDF | $4.34 -0.69% -0.69% 610K

Health Services

| -25.68% | O: 0.85% H: 5.73% C: -4.55%
ongoing preclinical meeting study

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024
Published: 2024-03-06 (Crawled : 21:00) - globenewswire.com
CRDF | $4.34 -0.69% -0.69% 610K

Health Services

| 12.34% | O: 1.54% H: 4.3% C: -11.14%
meeting

Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
Published: 2024-02-29 (Crawled : 21:00) - globenewswire.com
CRDF | $4.34 -0.69% -0.69% 610K

Health Services

| 147.59% | O: 13.31% H: 53.5% C: 45.5%
business year update results

Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC
Published: 2024-02-29 (Crawled : 21:00) - globenewswire.com
CRDF | $4.34 -0.69% -0.69% 610K

Health Services

| 147.59% | O: 13.31% H: 53.5% C: 45.5%
update trial

Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)
Published: 2024-02-29 (Crawled : 21:00) - globenewswire.com
CRDF | $4.34 -0.69% -0.69% 610K

Health Services

| 147.59% | O: 13.31% H: 53.5% C: 45.5%
crdf-004 first cancer trial

Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update
Published: 2024-02-22 (Crawled : 13:00) - globenewswire.com
CRDF | $4.34 -0.69% -0.69% 610K

Health Services

| 160.12% | O: 1.19% H: 1.76% C: -0.59%
report business year update results

Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research
Published: 2024-01-17 (Crawled : 15:30) - prnewswire.com
CRDF | $4.34 -0.69% -0.69% 610K

Health Services

| 168.1% | O: -2.45% H: 2.52% C: -7.55%
cancer publication research study

Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference
Published: 2023-11-20 (Crawled : 21:00) - prnewswire.com
CRDF | $4.34 -0.69% -0.69% 610K

Health Services

| 276.72% | O: 0.0% H: 1.72% C: -0.86%
conference

Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business Update
Published: 2023-10-26 (Crawled : 20:00) - prnewswire.com
CRDF | $4.34 -0.69% -0.69% 610K

Health Services

| 324.27% | O: 0.63% H: 5.11% C: 1.3%
report business update financial results

Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy
Published: 2023-09-26 (Crawled : 20:00) - prnewswire.com
CRDF | $4.34 -0.69% -0.69% 610K

Health Services

| 169.75% | O: 17.9% H: 4.97% C: -16.23%
lung positive onvansertib cancer pancreatic cell

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001628280-24-009748	4	2024-03-07	2024-03-07	Buy	A	205008	962496
0001628280-24-009747	4	2024-03-07	2024-03-07	Buy	A	205008	630008
0001628280-24-009746	4	2024-03-07	2024-03-07	Buy	A	205008	647184
0001628280-24-009745	4	2024-03-07	2024-03-07	Buy	A	510000	2170310